Life Sciences Law & Industry Report connects the dots among the many disciplines that make up the burgeoning life sciences industry, with biweekly updates on current regulatory, legislative,...
May 2 — Immunosyn Corp.'s former chief executive officer misled investors that human trials were starting in Europe and didn't mention the FDA had put a hold on a goat-blood derived product, a jury found April 29.
A jury of the U.S. District Court for the Northern District of Illinois found Stephen D. Ferrone liable for violations of Section 10(b) of the Securities Exchange Act for making false statements and omissions and of Securities Exchange Act Rule 13(a) for making false certifications. The jury didn't find Ferrone liable for aiding and abetting the making of false certifications.
The Securities and Exchange Commission said it was pleased with the jury's finding that Ferrone had, as the SEC alleged, defrauded Immunosyn’s investors with misleading statements in the company’s filings and press releases and in his own speeches and interviews.
“We will continue to hold executives accountable when their companies provide misleading information and fail to give investors a full and honest picture of what’s happening with their products,” Andrew Ceresney, director of the SEC’s Division of Enforcement, said in a statement.
The SEC alleged in August 2011 that Immunosyn had issued misleading filings from 2006 to 2010 by saying that its controlling shareholder, Argyll Biotechnologies LLC, had initiated, or intended to initiate, proceedings to obtain U.S. regulatory approval for human clinical trials for its only product, SF-1019 (5 LSLR 808, 8/12/11). In fact, the SEC asserted, the filings didn't inform investors that the FDA had twice issued clinical holds to bar clinical trials from occurring for SF-1019, intended for treatment of diabetes-related inflammatory and degenerative conditions.
In addition, the SEC alleged that the company falsely stated that the regulatory approval process for human clinical trials in Europe was underway or imminent, when in fact Argyll didn't submit applications for such trials. The agency also alleged that Immunosyn Chief Financial Officer Douglas McClain Jr., Argyll Chief Scientific Officer Douglas McClain Sr. and Argyll Chief Executive Officer James Miceli had engaged in insider trading by raising about $20 million through sales of Immunosyn shares while knowing that the misrepresentations were being made.
Miceli committed suicide before the trial began.
The SEC experienced mixed results six months ago in its claims against two other Immunosyn executives.
In October 2014, the court found McClain Sr. and McClain Jr. liable for making fraudulent misstatements and for insider trading (8 LSLR 1071, 10/31/14). A year later, it granted the SEC's bid for permanent injunctive relief and civil money penalties but declined to order disgorgement and lifetime officer/director bars.
In the Ferrone litigation, the SEC was represented by attorneys out of its Chicago office and Ferrone by Stetler, Duffy & Rotert, Ltd., Chicago.
To contact the reporter on this story: John T. Aquino in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at firstname.lastname@example.org
The docket entry of the jury verdict is at http://www.bloomberglaw.com/public/document/Securities_And_Exchange_Commission_v_Ferrone_et_al_Docket_No_111c/3.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)